CN112654623A - 新型氮杂三环类化合物的盐型、晶型及其用途 - Google Patents

新型氮杂三环类化合物的盐型、晶型及其用途 Download PDF

Info

Publication number
CN112654623A
CN112654623A CN201980055280.7A CN201980055280A CN112654623A CN 112654623 A CN112654623 A CN 112654623A CN 201980055280 A CN201980055280 A CN 201980055280A CN 112654623 A CN112654623 A CN 112654623A
Authority
CN
China
Prior art keywords
cancer
salt
compound
ray powder
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980055280.7A
Other languages
English (en)
Other versions
CN112654623B (zh
Inventor
徐晓峰
王家炳
丁列明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CN112654623A publication Critical patent/CN112654623A/zh
Application granted granted Critical
Publication of CN112654623B publication Critical patent/CN112654623B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

结构式I所示化合物的马来酸盐、甲磺酸盐、苯磺酸盐、盐酸盐、磷酸盐、L‑酒石酸盐、L‑苹果酸盐、柠檬酸盐和富马酸盐，及各盐型的多种晶型，其制备方法及其应用。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201980055280.7A 2018-08-27 2019-08-27 新型氮杂三环类化合物的盐型、晶型及其用途 Active CN112654623B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018102549 2018-08-27
CNPCT/CN2018/102549 2018-08-27
PCT/CN2019/102720 WO2020043078A1 (zh) 2018-08-27 2019-08-27 新型氮杂三环类化合物的盐型、晶型及其用途

Publications (2)

Publication Number Publication Date
CN112654623A true CN112654623A (zh) 2021-04-13
CN112654623B CN112654623B (zh) 2023-05-23

Family

ID=69642961

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980055280.7A Active CN112654623B (zh) 2018-08-27 2019-08-27 新型氮杂三环类化合物的盐型、晶型及其用途

Country Status (7)

Country Link
US (1) US20210340142A1 (zh)
EP (1) EP3845534A4 (zh)
JP (1) JP2021535143A (zh)
KR (1) KR20210050530A (zh)
CN (1) CN112654623B (zh)
TW (1) TW202024084A (zh)
WO (1) WO2020043078A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502681A1 (de) * 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt Elektrophotographisches aufzeichnungsmaterial
CA2479644A1 (en) * 2002-04-03 2003-10-09 F. Hoffmann-La Roche Ag Imidazo fused compounds
CN105481858B (zh) * 2014-10-11 2019-05-17 上海医药集团股份有限公司 一种含氮稠杂环化合物、其制备方法、组合物及应用
KR20180002053A (ko) * 2016-06-28 2018-01-05 한미약품 주식회사 신규한 헤테로시클릭 유도체 화합물 및 이의 용도
EP3587419A4 (en) * 2017-02-27 2020-08-05 Betta Pharmaceuticals Co., Ltd. FGFR INHIBITOR AND APPLICATION OF IT

Also Published As

Publication number Publication date
TW202024084A (zh) 2020-07-01
CN112654623B (zh) 2023-05-23
US20210340142A1 (en) 2021-11-04
EP3845534A4 (en) 2022-04-06
JP2021535143A (ja) 2021-12-16
EP3845534A1 (en) 2021-07-07
WO2020043078A1 (zh) 2020-03-05
KR20210050530A (ko) 2021-05-07

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
EP3307732A1 (en) Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
CN112424202B (zh) 抑制cdk4/6活性化合物的晶型及其应用
CN111788197A (zh) 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途
US9120815B2 (en) Solid state forms of macrocyclic kinase inhibitors
CN113087671A (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CN112654623B (zh) 新型氮杂三环类化合物的盐型、晶型及其用途
US20220213060A1 (en) Crystal Form of Quinazolinone Compound and Preparation Method Therefor
WO2023230968A1 (zh) Shp2抑制剂、其晶型及其制备方法与用途
EP4353729A1 (en) Polymorph of imidazolidinone compound, preparation method therefor and use thereof
WO2023041061A1 (zh) 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
TW201829398A (zh) 酪胺酸蛋白激酶調節劑、晶型及其用途
CN117794902A (zh) ErbB和BTK抑制剂的新型药用盐和多晶型形式
CN115551863A (zh) 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
KR20220159457A (ko) Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도
TW202313034A (zh) Egfr抑制劑的鹽、晶型及其組合物和應用
CN117209500A (zh) Shp2抑制剂、其晶型及其制备方法与用途
CN114555558A (zh) 化合物的盐及其晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042843

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant